Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S (2020)

Publication Type: Journal article

Publication year: 2020

Journal

ACR Open Rheumatology Wiley

Book Volume: 2

Pages Range: 18-25

Journal Issue: 1

DOI: 10.1002/acr2.11097

Abstract

ObjectiveTo report the 5-year efficacy and safety of secukinumab in the treatment of patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326).

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Swedish Medical Center US United States (USA) (US) Novartis AG CH Switzerland (CH) Monash University AU Australia (AU) Whipps Cross University Hospital GB United Kingdom (GB) University of California, San Diego US United States (USA) (US) Dallas VA Medical Center US United States (USA) (US) Hasselt University / Universiteit Hasselt BE Belgium (BE)

How to cite

APA:

Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2020). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatology, 2(1), 18-25. https://doi.org/10.1002/acr2.11097

MLA:

Mease, Philip J., et al. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study." ACR Open Rheumatology 2.1 (2020): 18-25.

BibTeX: Download